09:10 AM EDT, 10/20/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Monday it signed a royalty financing deal with DRI Healthcare Acquisitions for up to $300 million.

Under the royalty agreement, the company said it will receive up to $300 million, which includes a $55 million upfront payment and $115 million tied to key clinical and regulatory milestones for its VRDN-003 and veligrotug programs in thyroid eye disease.

Viridian said it will pay tiered royalties on US sales of veligrotug, starting at 7.5% for sales up to $600 million and decreasing for higher sales levels.

The funds are expected to fully support commercial launches of veligrotug and VRDN-003, Viridian said.

Viridian also said it amended its credit facility with Hercules Capital, providing access to up to $300 million in capital upon meeting milestones and improving payment terms.

The company added that a biologics license application submission for veligrotug is "expected imminently."

Shares of Viridian were nearly 5% higher in recent premarket activity.